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Abstract
Bronchiectasis is a common feature of severe inherited and acquired pulmonary disease conditions. Among
inherited diseases, cystic fibrosis (CF) is the major disorder associated with bronchiectasis, while acquired
conditions frequently featuring bronchiectasis include post-infective bronchiectasis and chronic obstructive
pulmonary disease (COPD). Mechanistically, bronchiectasis is driven by a complex interplay of inflammation
and infection with neutrophilic inflammation playing a predominant role. The clinical characterization and
management of bronchiectasis should involve a precise diagnostic workup, tailored therapeutic strategies
and pulmonary imaging that has become an essential tool for the diagnosis and follow-up of bronchiectasis.
Prospective future studies are required to optimize the diagnostic and therapeutic management of
bronchiectasis, particularly in heterogeneous non-CF bronchiectasis populations.
Background
Bronchiectasis is a condition in which an area of the
bronchial lumen is permanently and abnormally
widened, with accompanying infection. Bronchiectasis is
found in a variety of pulmonary diseases, both genetic-
ally caused and acquired, such as severe pulmonary
infections and cystic fibrosis (CF), but is also a feature of
Kartagener syndrome, chronic obstructive pulmonary
diseases (COPD), alpha 1-antitrypsin deficiency, asthma,
or primary immunodeficiencies [1–3]. Bronchietasis is
caused by long-term excessive inflammatory damage to
the airways, which results in tissue breakdown, enlarge-
ment of the affected airways and the key clinical symp-
toms of chronic productive cough and shortness of
breath. Globally, in up to half of all cases the cause can-
not be identified (idiopathic). Those cases together with
several other known aetiologies such as post-infectious
and allergic hypersensitivity collectively fall under the
category ‘non-cystic fibrosis’ (non-CF) bronchiectasis
[4]. Here we discuss the key features of both CF and
non-CF related bronchiectasis with respect to their
pathogenesis, imaging and clinical management.
Pathogenesis of bronchiectasis formation
Bronchiectasis mechanistically results from chronic in-
flammatory microenvironments that trigger airway tissue
breakdown. In both CF and non-CF bronchiectasis, the
complex interplay between infection and inflammation
feeds a pro-inflammatory vicious circle that progressively
drives the generation of bronchiectasis and the destruc-
tion of the pulmonary architecture [5]. Inflammatory
immune cells (mainly activated macrophages and
neutrophils) represent the major infiltrating population
in disease conditions associated with bronchiectasis and
contribute significantly to tissue damage and bronchiec-
tasis generation through the release of their harmful cel-
lular ingredients. Particularly, cell-derived proteases and
reactive oxygen species represent key mediators in the
degradation and destruction of extracellular pulmonary
tissue components, leading to bronchiectasis formation.
The precise early immune-mediated mechanisms that
trigger and maintain the formation of bronchiectasis
remain yet incompletely understood. Regulated immune
homeostasis seems to be essential since both immune
deficiencies as well as hyper-active immune responses
are associated with bronchiectasis. Particularly, the
protease-antiprotease imbalance [6, 7], as found in CF
and COPD airways, is considered as key pathogenic
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component in degrading extracellular matrix. Mutations
in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene are causative for CF lung disease
and drive the earliest pathogenic events in epithelial cells
that ultimately lead to the genesis of bronchiectasis. Also
beyond CF lung disease, CFTR-related cellular me-
chanisms regulating mucociliary clearance have been
involved in cigarette smoke-induced COPD [8].
In the following two sections, we will focus on the micro-
biological (a) and immunological/inflammatory (b) findings
associated with the pathogenesis of bronchiectasis.
Microbiology
Pseudomonas aeruginosa is a common and dominant
pathogen found in the airways of both CF and non-CF bron-
chiectasis patients [9–13]. Chronic infection has been associ-
ated with more severe decline in lung function [14–19],
increased hospitalizations [20, 21], frequent exacerbations
[22] and disease severity [23, 24]. Although clinical manifes-
tations between the two settings vary, their core airway
microbiota is largely analogous [25]. Along with Pseudo-
monas, bacteria belonging to other genera such as Haemoph-
ilus, Streptococcus, Staphylococcus,Veillonella, Prevotella and
Achromobacter also make up the core microbiota observed
in bronchiectasis [9, 26, 27]. Interestingly, P. aeruginosa and
H. influenzae have been described to competitively inhibit
each other, which in turn alters the core microbiota in the
non-CF bronchiectasis airway [28]. Non-tuberculous myco-
bacteria (NTM) form another significant group of pathogens
colonizing CF and non-CF airways [29–31]. Mycobacterium
avium complex (MAC) and Mycobacterium abscessus are
most frequently isolated in CF [32, 33] with high rates of
multi-drug resistance in these species making them
notoriously difficult to treat [34]. NTM belonging to the
MAC group are also highly prevalent in non-CF bronchiec-
tasis with a female preponderance [35, 36]. This group of
organisms are surprisingly poorly associated with disease
severity and exacerbations in the non-CF setting when com-
pared to Pseudomonas [37, 38]. In contrast for CF patients,
MAC and M. abscessus are often associated with an aggres-
sive and accelerated lung function decline [39–42]. Interest-
ingly, bacterial populations do not drastically change
between stable and exacerbation states in bronchiectasis.
However, viral load has been positively correlated with
exacerbations in both CF and non-CF bronchiectasis pa-
tients. Infection with viruses belonging to the coronavirus,
rhinovirus and influenza A/B virus families are frequently de-
tected during exacerbations of bronchiectasis [43–45].
Whether the occurrence of such viruses, forming part of the
airway ‘virome’ in bronchiectasis, are a cause or consequence
of exacerbations remains to be elucidated [43, 46]. Most
attention towards understanding the microbiome in bronchi-
ectasis is directed at the bacteriome. Although fungi are
frequently isolated from the same airways, the role of the
pulmonary mycobiome in the pathogenesis of these disease
states remains largely elusive [47–49]. Filamentous fungi
belonging to the genus Aspergillus are frequently
isolated fungal organisms in sputum samples from CF
patients [50, 51]. Among the different species of As-
pergillus, A. fumigatus is the most common chronic
colonizer in CF [47, 52] Allergic bronchopulmonary
aspergillosis (ABPA), an allergic Aspergillus-associated
disease, is a frequent co-morbidity in CF [53], while
Aspergillus colonization and sensitization has also
been independently correlated with lung function de-
clines and radiological severity in CF [54–56]. Only a
single study to date has shown that fungi belonging
to the Aspergillus spp. and Candida albicans are also
identifiable in the airways of non-CF bronchiectasis
patients [57]. Importantly, in a study of severe asthma
patients, Aspergillus fumigatus sensitization has also
been associated with poorer lung function and an
increased incidence of bronchiectasis, a likely cause
and consequence for this anatomical airway distortion
[58, 59]. Among yeasts, Candida spp. are frequent
colonizers of the bronchiectatic airways [47, 57, 60].
Isolation of Candida albicans from such airways is
shown to be a predictor for frequent hospital-
exacerbations and declines in lung function [61].
Compared to bacteria, our present understanding of
fungal pathogenesis in the context of both CF and
non-CF bronchiectasis remains limited and further
work is required to determine their prevalence,
colonization frequency, host-pathogen interaction and
risk factor profile in this key patient group.
Immunology & inflammation
Neutrophil-dominant inflammation is a key feature of
bronchiectasis. Sputum neutrophils are higher in bronchi-
ectasis patients versus healthy controls and this correlates
with an increased disease severity [62–64]. Both
interleukin-8 (IL-8) and leukotriene-B4 (LTB4) are key
chemo-attractants required for migration and infiltration
of neutrophils into bronchiectatic airways [65]. High
systemic IL-8 levels are detectable in individuals with
bronchiectasis [66–68]. Antibacterial neutrophil responses
(such as reactive oxygen species (ROS) formation) are ac-
tivated through the IL-8-CXCR1 axis, but proteolytic
cleavage mediated by neutrophil elastase (NE), which itself
is associated with exacerbations and lung function decline
in bronchiectasis, impairs antibacterial neutrophil func-
tions [69, 70]. Uncontrolled NE activity, as found in CF
airways, causes further respiratory tissue damage through
degradation of extracellular proteins (such as surfactant
proteins [71–73]) and cellular surface receptors (such as
complement receptors [74]); high NE levels correlating
with disease severity and poorer lung function are
described in both CF and non-CF bronchiectasis settings
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[75, 76]. In this context, CXCR receptor antagonists are
hypothesized to inhibit neutrophil airway influx and have
been shown to be effective in modulating the inflamma-
tory state in bronchiectasis [77, 78]. Airway neutrophils in
CF illustrate an impaired phagocytic ability [79]. This is in
line with the observation that CF neutrophils have an
impaired ROS production, a critical mediator of anti-
microbial host defense [80]. Neutrophils defective in their
oxidative abilities obtained from non-CF bronchiectasis
patients were poorer at bacterial killing when compared to
those of healthy controls [81]. Serine proteases are also
important neutrophil derived products, released in re-
sponse to TNF-α signalling. They degrade proteoglycans
in the respiratory epithelium subsequently inducing
airway damage [82]. In bronchiectasis, activated airway
neutrophils secrete an abundance of human neutrophil
peptides (HNPs), which have been described to inhibit
their phagocytic ability. Importantly, high concentrations
of HNPs are detected in both CF and non-CF airways,
which in turn may contribute to the decreased phagocytic
abilities and higher rates of infection described in both
conditions [83]. Poorer clearance of neutrophils by alveo-
lar macrophages further augments the inflammatory state
in bronchiectasis [63]. Eosinophils contribute to tissue in-
jury in CF and the presence of eosinophil cationic protein
(ECP) heralds the cell activation state. ECP levels are ele-
vated both in the airway and systemically in bronchiectasis
[84–86]. Other eosinophilic markers including eosinophil
protein X and peroxidase follow a similar pattern and like
ECP contribute to poorer pulmonary function [87]. Im-
portantly, eosinophilic granule release in CF may be
triggered by NE illustrating the cross-granulocyte talk that
occurs in the setting of bronchiectasis [88]. T-cells
constitute another key component of the inflammatory re-
sponse in bronchiectasis [89]. In CF, high T-helper 2 (Th2)
[90, 91] and Th17 [91] responses are observed. Th2 cyto-
kines such as IL-4, − 13 and TARC/CCL17 are correlated
with a decreased pulmonary function in CF-Pseudomonas-
colonized patients. Th17 cells, neutrophils and NKT cells
are found in abundance in all-cause bronchiectasis com-
pared to healthy controls [92]. While high Th17 infiltrates
independently associate with poorer lung function in CF
[93], activation of Th17 antigen-specific pathways have
been described in non-CF bronchiectasis [94]. IL-17, a cen-
tral mediator of the Th17 pathway lacks correlation with
bronchiectasis disease phenotypes suggestive of the more
prominent role that neutrophil-mediated inflammation
likely plays in the pathogenesis of bronchiectasis [94]. Both
CD8+ T cells and NKT that express pro-inflammatory IFN-
γ and TNF-α have been described in paediatric bronchiec-
tasis [95]. Common pro-inflammatory markers such as
TNF-α, IL-8, NE and matrix metalloproteinases − 2, − 8
and − 9 (MMP2, MMP8 and MMP9), are all elevated in
bronchiectasis with the latter two indicative of a poorer
prognostic outcome [96–100]. A seminal study in CF chil-
dren identified the key risk factors for bronchiectasis: Sly et
al. (2013) showed that elevated airway neutrophil elastase
activity was major risk factor and predicted bronchiectasis
development [101, 102]. Bacterial load in non-CF bronchi-
ectasis has been correlated with increases in airway (NE,
IL-8, IL-1β and TNF-α) and systemic (ICAM-1, E-selectin)
derived inflammatory markers, phenomena confirmed in
vitro using bronchial epithelial cell lines treated with spu-
tum from bronchiectasis patients [103, 104]. Exacerbations
of both CF and non-CF bronchiectasis increases inflam-
mation irrespective of bacterial, viral or fungal causation
[43, 105, 106]. Interestingly, sTREM-1 a novel inflammatory
marker described in a variety of pulmonary disease states
including COPD, has also been identified in children with
both CF- and HIV-related bronchiectasis although concen-
trations in the latter setting are highest. High sTREM-1
levels correlate closely with lung function decline and
future studies should explore sTREM-1 levels in bronchiec-
tasis of other aetiologies to better understand its role in the
pathogenesis of bronchiectasis [107]. Vitamin-D deficiency,
observed in CF [108, 109] is associated with increased bac-
terial infection, exacerbations and poorer lung function
[110–112]. This is corroborated in non-CF bronchiectasis
where it indicates disease severity and associates with more
infection, bacterial colonization, airway inflammation and
consequently frequent exacerbations [113].
Clinical characteristics and management of
bronchiectasis
Bronchietasis patients are clinically characterized by spu-
tum production (upon exercise or spontaneously) leading
to productive coughing with mucopurulent masses of
yellowish, greenish or brown sputum in the morning or
over the day. However, bronchiectasis are mainly detected
at time points when irreversible structural damage has
already been done to the airway architecture. Bronchiec-
tasis initially may be reversible in children, later probably
not. Major genetic diseases associated with bronchiectasis
include CF, primary ciliary dyskinesia (PCD, Kartagener
syndrome), alpha 1-antitrypsin deficiency, primary
immunodeficiencies or other rare disorders like Williams-
Campbell syndrome and Marfan syndrome. Major ac-
quired causes are severe bacterial infections (Tuberculosis,
Staphylococcus, Klebsiella and others) or postinfectious
bronchiolitis obliterans. Notably, also fungal infections
can lead to bronchiectasis, particularly ABPA, as a chronic
Th2-driven Aspergillus fumigatus-caused pulmonary con-
dition. Based on this, it is essential in the clinical work-up
of patients featuring bronchiectasis to screen for these
congenital and acquired conditions in order to tailor ap-
propriate treatments and to attenuate disease progression.
In a preventive manner, it is key in the above mentioned
conditions to diagnose and monitor for pulmonary
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symptoms and structural changes (using pulmonary func-
tion testing and high-resolution computed tomography,
HRCT) to avoid established bronchiectasis-related disease.
To this end, it is helpful to follow a concept that has been
introduced previously to classify forms of bronchitis in
children [114–116]. An acute bronchitis, usually triggered
by a viral infection, resolves within days or one to two
weeks. Sometimes – for many reasons of which most are
unknown – symptoms do not resolve spontaneously, but
persist. This state is called protracted bacterial bronchitis
(PBB). While PBB has been initially established for
pediatrics, current publications have discussed and trans-
ferred this concept to adults {Birring, 2015 #16382;Gibson,
2010 #16381;Martin, 2015 #16380}. PBB is further differ-
entiated into various forms, depending on the tools used
to diagnose it [114, 115]. PBB can be further characterized
based on different stratifiers:
 PBB-microbiologic (“PBB-micro”): (1) presence of
chronic wet cough (> 4 weeks), (2) respiratory
bacterial pathogens growing in sputum or BAL at
density of a single bacterial specifies > 104 colony-
forming units/ml, and (3) cough resolves following a
2-week course of an appropriate oral antibiotic
(usually amoxicillin-clavulanate)
 PBB-clinical: (1) presence of chronic wet cough
(> 4 weeks), (2) absence of symptoms or signs of
other causes of wet or productive cough, (3)
cough resolves following a 2-week course of an
appropriate oral antibiotic (usually amoxicillin-
clavulanate)
 PBB-extended: as above, but cough resolves only
after 4 weeks of antibiotics
 PBB-recurrent: > 3 episodes of PBB per year
Based on this concept, it is believed that, if left
untreated, a fraction of PBBs will progress to chronic
suppurative lung disease (CSLD) with radiologically
confirmed bronchiectasis (Fig. 1). CSLD differs from
bronchiectasis only by lacking the radiographic signs of
bronchiectasis on HRCT scans. Clinically, CSLD is
diagnosed in children whose chronic wet cough does not
resolve with oral antibiotics and in whom other causes
are excluded [117, 118]. Although not proven formally
for all causes of bronchiectasis, the sequence of progres-
sion from PBB over CSLD to bronchiectasis is highly
likely, but needs to be substantiated with prospective
studies. Of interest is the recent finding that otherwise
healthy children with PBB, children with bronchiectasis,
and children with CF shared similar core airway micro-
biota patterns, with H. influenzae making the greatest
contribution to the observed similarity, while the micro-
biota in adults with CF and bronchiectasis were signifi-
cantly different [25]. The authors concluded that chronic
airway infections starts similarly with defective airway
clearance, but over time with intervention and host
factors, i.e. the underlying cause, progressively diverge.
The prevalence of bronchiectasis in children with CF
has recently been assessed in studies conducted by the
Australian Respiratory Early Surveillance Team for Cys-
tic Fibrosis (AREST CF) and others. Although 50–70%
of CF patients have CT-defined bronchiectasis by 3 to
5 years of age [119], most young children have isolated,
i.e. localized disease, with only the mildest severity of
lung abnormalities and lobar disease extent that is well













Fig. 1 Model of disease progress towards bronchiectasis in patients with and without CF. Modified from Chang et al. [115]
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once established, bronchiectasis persists and/or
progresses despite current optimized standard-of-care
therapies in about 75% of young children [121, 122].
Currently great effort is undertaken to close the diagnos-
tic gap from 0 to about 5 years of age, to non-invasively
assess the extent of lung disease. The PRAGMA-CF
score was developed as a sensitive and reproducible out-
come measure for assessing the extent of lung disease in
very young children with CF [123]. Moreover, the lung
clearance index is a measure of ventilation distribution
obtained by the multiple-breath washout technique. Se-
veral studies have shown its sensitivity to airway disease
in CF and other bronchial diseases [124, 125]. However,
in infants with CF, lung clearance index was insensitive
to structural disease, as assessed by PRAGMA scoring
[126]. In preschool and school-age children with CF’s
lung clearance index correlated with total disease extent.
Of interest, it had good positive predictive value of
about 85%, but a poor negative predictive value of
55% to detect bronchiectasis. Therefore, lung clear-
ance index may be a good surveillance tool to
monitor structural lung disease up to school-age in
CF [126]. In an effort to identify the preceding-stages
of bronchiectasis in CF children by using at least four
consecutive biennial volumetric CTs, areas with bron-
chiectasis on CT scans were marked, further analyzed
and associated to potential pre-stages, which were
mucus plugging (18%), airway wall thickening (2%) or
atelectasis/consolidation in 1% [127].
The basic clinical management of bronchiectasis includes
tailored antimicrobial therapy and airway clearance tech-
niques. The latter include mucolytics, such as hypertonic
saline and rhDNA, as well as chest physiotherapy and
vigorous physical sporting activities. In PBB, oral antibiotics
for 2 weeks up to several months have been described to be
helpful. Antibiotics commonly used in the clinics include
amoxicillin, amoxicillin-clavulanate or second generation
cephalosporins. Particularly in patients with CF, gram-
negative organisms are treated with inhaled tobramycin, co-
listin, actreonam or levofloxacin as well as oral inhibitors of
gyrases, i.e. ciprofloxacin. The duration of treatment should
be guided by symptoms; goal is a symptom-free patient.
This can be mostly achieved in young children or patients
in the stages of PBB, CSLD and the early stages of bronchi-
ectasis. More specific treatment strategies in bronchiectasis
depend on the underlying etiology and include protein aug-
mentation (alpha 1-antitrypsin deficiency), anti-allergic ap-
proaches (asthma/ABPA) and/or immunoglobulin
substitution (immunodeficiencies).
Imaging of bronchiectasis in CF lung disease
Detection and characterization of bronchiectasis are the
domain of thin-section computed tomography (CT).
High-resolution CT (HRCT) with 0.6 to 1.5 mm slice
thickness serves as a reference standard for imaging.
However, pulmonary MRI has gained interest due to the
possibility of functional imaging without radiation bur-
den. Moreover, new technical developments overcome
the limitations of low MR-signal and low spatial
resolution. In CF, standardized reporting using scores or
automated quantification are essential requisites to
measure and track findings, particularly when results
focus on risk stratification. In this context, bronchiec-
tasis is one of the important imaging markers and
generally correlates with clinical outcome.
Imaging characteristics of bronchiectasis
Bronchiectasis is defined as irreversible dilation of
bronchi in cylindrical, varicose, or a more cystic
morphological appearance. In CF, it is often associated
with mucus plugging, bronchial wall thickening, and
small airway disease [128, 129]. The radiological evalu-
ation of bronchiectasis is based on definition published
in the terms for thoracic imaging of the Fleischner Soci-
ety [130]: “Morphologic criteria on thin-section CT scans
include bronchial dilatation with respect to the accom-
panying pulmonary artery (signet ring sign), lack of
tapering of bronchi, and identification of bronchi within
1 cm of the pleural surface.” The so-called signet ring
sign is the primary sign for bronchiectasis representing a
ring-shaped opacity, whereas the smaller adjacent artery
stays for the signet. According to this concept, the
extent of bronchial dilation can be quantified using the
ratio between bronchi and vessels [128], an approach
challenged by a recent pediatric study [131]. On HRCT,
the bronchial tree is only visible up to the 6-8th gener-
ation [130]. CT findings like the tree-in-bud sign and
centrilobular opacity are linked to small airway disease
with dilation and inflammation of the ronchiole or
mucus plugging in its periphery (Fig. 2) [130]. There are
differences in CF bronchiectasis depending on pancreas
insufficiency (PI), with PI patients illustrating more se-
vere bronchiectasis [132]. Primary ciliary dyskinesia
(PCD) patients have similar CT scores as pancreatic-
sufficient (PS) CF patients, but in contrast to CF, no
correlation between structural change and clinical pa-
rameters has been detected in a previous study [133].
However, recent studies in adult PCD patient cohorts in-
dicate that CT findings relate to lung function changes
[134, 135]. There are no clear identifiers of pre-
bronchiectasis in imaging. However, mucus plugging has
been shown to be a common precursor in CF [127].
Imaging can illustrate lung damage even when lung
function (such as forced expiratory volume in 1 s, FEV1)
is normal [128, 136, 137] (Fig. 3). In contrast to imaging,
pulmonary function tests (PFT) are challenging in young
children. A complementary role with lung clearance
index (LCI) has been described [138]. Regarding the
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evaluation of the presence and extent of bronchiectasis,
CT imaging is accepted as the most sensitive and repro-
ducible modality to date. Using new generation dual
source multidetector CT (MDCT) maintaining sub-
second acquisition of the whole lung breathing and pul-
sation artifacts are negligible even in young children and
no sedation is needed [139, 140]. Finally, using spectral
beam shaping and iterative reconstruction algorithms,
ultralow-dose pediatric chest CT can be realized with an
effective dose below 0.3 mSv [139]. These conditions,
therefore, challenge the routine use of MRI. On the
other hand, there are a couple of reasons supporting
MRI. The radiation burden of routinely performed volu-
metric chest CT may be many times higher than that of
a third generation of dual source CT recently published.
Incremental HRCT with significant gaps lowers the dose
but also diagnostic performance and leads to more mo-
tion artifact in the pediatric population [141]. Estimated
risk of radiation-induced cancer from a pediatric chest
CT is small but not negligible, particularly in cases of
repeated exposure [142, 143]. MRI has no side effects by
radiation enabling long-term surveillance of lung
damage. The overall diagnostic performance by scores
evaluation of MRI in direct comparison to CT is good to
excellent [144–146] (Fig. 4). Moreover, apart from
polarized 3+ Helium imaging, functional imaging can be
easily implemented using perfusion or ventilation
weighted standard proton MRI that assesses small
airway disease [146–149] (Fig. 5).
Clinical value
Standardized reporting of cross-sectional imaging by
scoring systems is suitable for several reasons: (a) to
assess and to quantify individual progression of lung
damage in comparison or complementary to lung
function testing, (b) to use total or partial score
values as endpoints for interventional studies, and (c)
to establish predictive imaging biomarkers. Most CT
scoring systems use a semiquantitative scale for the
extent and severity of specific findings either based
on lobe, involved bronchopulmonary segments, or
using an overlay grid [128, 129, 150]. According to
the disease-specific prevalence from the imaging
Fig. 2 15 y/o male, CF-patient, FEV1 predicted 45%. Thin-section
HR-reconstruction from MDCT (effective dose of 1.5 mSv). Severe
bronchiectasis is visible. Note also dilated bronchi within the periphery
of the lung. Air trapping is noted, only in central parenchyma, the CT
attenuation appears normal (asterisks)
Fig. 3 6 y/o female CF-patient, FEV1 predicted 105%. Thin-section
HR-reconstruction from MDCT (effective dose of 1 mSv). Mild
bronchiectasis, bronchial wall thickening (arrows) and mosaic
attenuation (asterisk) are visible
R L
Fig. 4 29 y/o male CF-patient, FEV1 predicted 67%. Left side CT,
right side MRI at the same day. Upper row, transverse thin-section
images from 3D acquisition in breath hold (CT and MRI). Note,
despite lower resolution and signal to noise a similar depiction of
bronchiectasis is possible. Lower row, expiration images (transverse
CT and saggital MRI). In both modalities focal air trapping within the
same lung region is demonstrated (arrow heads)
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abnormalities, sub-scores for bronchiectasis and bron-
chial wall thickening are more heavily weighted (1, 2).
Inter-observer and intra-observer agreement of the
common CT scores has shown to be good to
excellent [128, 129]. Comparable reproducibility has
also been found for MRI using CT or MR-specific
adapted scoring systems in small numbers of studies
[144, 148]. For semiautomatic evaluation of bronchi
dimension excellent inter-observer agreement has
been found particularly for the bronchial lumen [151].
On the other hand, mucus can obscure or mimic bron-
chial wall thickening. Apart from reproducibility, the
weighting of abnormalities within the scores, and valid-
ation are even more challenging and related to the pur-
pose and the use of score (e.g. interventional or clinical
study). As aforementioned imaging is more sensitive than
FEV1 particularly in mild disease, and, in assessment of
disease progression [128, 136, 137, 152]. In this context
scoring of bronchiectasis particularly in the lung periphery
is important [137], whereas air trapping, mosaic perfusion,
and mucus plugging seem to be more sensitive markers
than CT or MRI which detect effects of interventions
[153, 154]. The role of bronchiectasis as a robust
predictive marker has been shown in several longitudinal
observations [150, 155–159]. The extent of bronchiectasis
at baseline can predict the number of respiratory tract
exacerbations (RTE) [155–158], and the change of the
subscore in a two year follow up is strongly associated
with numbers of RTEs where FEV1 did not provide value
[156]. This has been similarly described for a decade long
observational study [158]. In an older study, a maximum
combined score for bronchiectasis and emphysema on
HRCT was indicative of a poorer prognosis [159]. In a re-
cent study of patients with severe lung disease awaiting
lung transplantation, the combined score of bronchiec-
tasis, bronchial wall thickening, mucus, and consolidation
was associated with mortality [150].
Conclusions
Bronchiectasis is a heterogeneous and complex condition
and remains a challenge for both diagnostic and
therapeutic strategies. While pathomechanisms in the
pulmonary compartment share commonalities from a
microbiological and immunological perspective, clinical
implications and treatment approaches remain challen-
ging and individualized, depending on the underlying
disease and the infection status. High-resolution imaging
has revolutionized the diagnosis and monitoring of bron-
chiectasis and will further pave the way for a more precise
understanding of disease pathogenesis and treatment re-
sponse in the future. Therapeutically, lessons learned from
the well-known phenotype of CF bronchiectasis are in-
creasingly transferred to the multifaceted genotype and
phenotype of non-CF bronchiectasis. Airway infections
are treated with inhaled and systemic antibiotics. Mucus
clearance can be improved by inhaled therapies and chest
physiotherapy, whereas specific anti-inflammatory
approaches have still not been clinically established. Pro-
spective future studies are urgently needed to optimize
the diagnostic and therapeutic management of bronchiec-
tasis, particularly in children with non-CF bronchiectasis,
an indication with a high unmet medical need.
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